IL33 and lung carcinoma: Yang, Z. et al. (57) found that IL-33 treatment promoted the lung cancer cell migration as well as invasion and increased the expression of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) in a ST2-dependent manner.